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Two guidelines from the American College of Cardiology (ACC), the American
Heart Association (AHA), and collaborating societies address the risk of aortic
dissection in patients with bicuspid aortic valves and severe aortic enlargement:
The ‘‘2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guide-
lines for the Diagnosis and Management of Patients With Thoracic Aortic Dis-
ease’’ (J Am Coll Cardiol. 2010;55:e27-130) and the ‘‘2014 AHA/ACC
Guideline for the Management of Patients With Valvular Heart Disease’’ (J Am
Coll Cardiol. 2014;63:e57-185). However, the 2 guidelines differ with regard to
the recommended threshold of aortic root or ascending aortic dilatation that would
justify surgical intervention in patients with bicuspid aortic valves. The ACC and
AHA therefore convened a subcommittee representing members of the 2 guide-
line writing committees to review the evidence, reach consensus, and draft a state-
ment of clarification for both guidelines. This statement of clarification uses the
ACC/AHA revised structure for delineating the Class of Recommendation and
Level of Evidence to provide recommendations that replace those contained in
Section 9.2.2.1 of the thoracic aortic disease guideline and Section 5.1.3 of the
valvular heart disease guideline.of Thoracic and Cardiovascular Surgery c April 2016See Editorial Commentary page 967.The association between bicuspid aortic valve (BAV) and
dilatation of the aortic root and ascending aorta is well
established, as is the risk of aortic dissection in patients with
BAVand severe aortic enlargement. However, data are limited
with regard to the aortic diameter at which the risk of dissec-
tion is high enough to warrant operative intervention in pa-
tients who do not otherwise fulfill criteria for aortic valve
replacement (AVR) on the basis of severe aortic stenosis or
aortic regurgitation. Two guidelines from the American Col-
lege of Cardiology/American Heart Association (ACC/
AHA) and collaborating societies differed with regard to the
recommended threshold of aortic root or ascending aortic dila-
tation that would justify surgical intervention in such pa-
tients.1,2 A subcommittee representing members of the 2
writing committees, which met current organizationalpolicies for disclosure of relationships with industry
(Appendix 1), was convened to review the evidence, reach
consensus, and draft the present statement as an addendum
to both guidelines. The evidence table to support this
addendum is available as an Online Data Supplement. This
statement was approved by the 2 guideline writing commit-
tees, underwent peer review (Appendix 2), and received
formal approval by the ACC and AHA and endorsements by
partner/collaborating organizations. The following recom-
mendations replace those contained in Sections 9.2.2.1 and
5.1.3, respectively, of the original guidelines1,2 and use the
revised structure for delineating the Class of
Recommendation and Level of Evidence adopted by the
ACC/AHA Task Force on Clinical Practice Guidelines3
(Table 1, Recommendations Table, Table 2).
TABLE 1. Applying class of recommendation and level of evidence to clinical strategies, interventions, treatments, or diagnostic testing in patient
care* (updated August 2015)
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TABLE 2. Risk assessment combining STS risk estimate, frailty, major organ system dysfunction, and procedure-specific impediments
Low risk
(must meet
ALL criteria
in this column)
Intermediate
risk (any 1
criterion in this
column)
High risk (any 1 criterion
in this column)
Prohibitive risk
(any 1 criterion
in this column)
STS PROM* <4%
AND
4%-8%
OR
>8%
OR
Frailtyy None
AND
1 Index (mild)
OR
2 Indices (moderate
to severe)
OR
Predicted risk with
surgery of death or
major morbidity
(all-cause)>50% at 1 y
OR
Major organ system compromise
not to be improved
postoperativelyz
None
AND
1 Organ system
OR
No more than 2 organ
systems
OR
3 Organ systems
OR
Procedure-specific impedimentx None Possible procedure-
specific impediment
Possible procedure-specific
impediment
Severe procedure-specific
impediment
CKD, Chronic kidney disease; CNS, central nervous system; CVA, cerebrovascular accident (stroke); DL co2, diffusion capacity for carbon dioxide; FEV1, forced expiratory
volume in 1 s; GI, gastrointestinal; INR, international normalized ratio; LV, left ventricular; PROM, predicted risk of mortality; RV, right ventricular; STS, Society of Thoracic
Surgeons; and VKA, vitamin K antagonist. *Use of the STS PROM to predict risk in a given institution with reasonable reliability is appropriate only if institutional outcomes are
within 1 standard deviation of STS average observed/expected ratio for the procedure in question. ySeven frailty indices: Katz Activities of Daily Living (independence in feeding,
bathing, dressing, transferring, toileting, and urinary continence) and independence in ambulation (no walking aid or assist required or 5-m walk in<6 s). Other scoring systems
can be applied to calculate no, mild, or moderate-to-severe frailty. zExamples of major organ system compromise: Cardiac—severe LV systolic or diastolic dysfunction or RV
dysfunction, fixed pulmonary hypertension; CKD stage 3 or worse; pulmonary dysfunction with FEV1<50% or DL co2<50% of predicted; CNS dysfunction (dementia,
Alzheimer’s disease, Parkinson’s disease, CVA with persistent physical limitation); GI dysfunction—Crohn’s disease, ulcerative colitis, nutritional impairment, or
serum albumin<3.0; cancer—active malignancy; and liver—any history of cirrhosis, variceal bleeding, or elevated INR in the absence of VKA therapy. xExamples:
tracheostomy present, heavily calcified ascending aorta, chest malformation, arterial coronary graft adherent to posterior chest wall, or radiation damage. Reproduced from
Nishimura et al.2
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